GEAN — Genetic Analysis As Balance Sheet
0.000.00%
Last trade - 00:00
- NOK20.63m
- NOK9.78m
- NOK14.15m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | — | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 4.01 | 24.2 | 46.8 | 25.3 | 16.3 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 12.2 | 1.93 | 8.42 | 8.36 | 11.2 |
Total Inventory | |||||
Total Current Assets | 16.9 | 28 | 57.6 | 35.4 | 29.1 |
Net Property, Plant And Equipment | 3.13 | 1.62 | 1.59 | 8.14 | 6.19 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 45.6 | 55.6 | 83.5 | 64.4 | 53.5 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9.26 | 7.59 | 9.97 | 12.9 | 16 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 12.1 | 9 | 11.4 | 20.3 | 21.5 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 33.5 | 46.6 | 72.1 | 44.1 | 32 |
Total Liabilities & Shareholders' Equity | 45.6 | 55.6 | 83.5 | 64.4 | 53.5 |
Total Common Shares Outstanding |